I. Targeted therapy will become the main research direction of international lung cancer treatment To date, targeted therapy has indisputably become one of the main means of lung cancer treatment, and its fruitful research results make people feel that a new era of lung cancer treatment has arrived. With the in-depth research on signaling pathways, molecular targeted drugs targeting different targets have emerged, introducing a new field of clinical research on lung cancer and bringing new hope. Second, the drug resistance generated by single-target therapy leads to the limitation of targeted therapy for lung cancer With the deepening understanding of tumor biological behavior, targeted therapy for lung cancer has become a research hotspot. Although patients with EGFR mutated tumors have good results with their targeted therapy, their drug resistance remains a major clinical problem. 2004 was the first report of EGFR mutated tumors showing histological features of adenocarcinoma, with higher sensitivity to such targeted drugs and better prognosis than wild type (unmutated), but unfortunately, drug resistance still eventually occurs leading to malignant tumor progression. EGFR-targeted therapies, instances of drug resistance also demonstrate to some extent the limitations of targeting therapeutic strategies against a single gene. Multi-targeted lung cancer therapy will become the new mainstream Research on the causes of drug resistance has revealed that lung cancer signaling is a multi-targeted and multi-linked regulatory process, and multi-targeted inhibitors are more effective than EGFR single-targeted inhibitors in treating lung cancer. Single-target inhibitors can only block one signaling pathway, and cancer cells can remedy or escape through other pathways, or even activate the rapid amplification of other tumor genes, which eventually leads to lung cancer recurrence, metastasis and treatment failure. The Cleveland Cancer Research Center, USA, found that the activation of STAT3 and NFkB is one of the mechanisms of primary resistance to EGFR in lung cancer. The research group of Cleveland Cancer Research Center, USA was fortunate to find a natural substance called MCBM, which inhibits the EGFR pathway while employing multiple tumor signals acting on different targets in the nucleus, simultaneously turning off several tumor-causing signals such as EGFRNFkBSTAT3, choking off tumor activating genes, blocking tumor cell conduction signals from the root, allowing the original cancer cells It is especially suitable for cancer patients who have developed resistance to single-target inhibitors.